Wall Street Zen Downgrades Lifevantage (NASDAQ:LFVN) to Buy

Key Points

• Lifevantage has been downgraded from a "strong-buy" to a "buy" rating by Wall Street Zen, affecting investor sentiment.
• The company reported earnings of $0.17 per share for the last quarter, matching analyst estimates, but revenue fell short of expectations at $55.11 million compared to the estimated $57.93 million.
• Following recent transactions, insider ownership decreased, with 20.65% of the stock currently held by corporate insiders and several institutional investors increasing their stakes in the company.

Wall Street Zen downgraded shares of Lifevantage (NASDAQ:LFVN - Free Report) from a strong-buy rating to a buy rating in a report released on Saturday.

Lifevantage Stock Performance

LFVN traded down $0.35 during trading on Friday, hitting $11.49. The stock had a trading volume of 64,736 shares, compared to its average volume of 193,591. The firm has a market capitalization of $145.86 million, a P/E ratio of 15.54 and a beta of 0.39. The company's 50-day moving average price is $13.07 and its 200 day moving average price is $13.57. Lifevantage has a twelve month low of $9.00 and a twelve month high of $27.38.

Lifevantage (NASDAQ:LFVN - Get Free Report) last announced its quarterly earnings data on Thursday, September 4th. The company reported $0.17 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.17. The company had revenue of $55.11 million for the quarter, compared to analysts' expectations of $57.93 million. Lifevantage had a net margin of 4.29% and a return on equity of 33.75%. During the same period in the previous year, the company posted $0.14 EPS. Lifevantage has set its FY 2026 guidance at 1.000-1.15 EPS.

Lifevantage Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, September 16th. Shareholders of record on Monday, September 8th will be given a dividend of $0.045 per share. This represents a $0.18 annualized dividend and a dividend yield of 1.6%. The ex-dividend date is Monday, September 8th. Lifevantage's payout ratio is presently 24.32%.

Insider Activity at Lifevantage

In other Lifevantage news, CFO Carl Aure sold 2,746 shares of the business's stock in a transaction on Tuesday, July 1st. The stock was sold at an average price of $13.39, for a total transaction of $36,768.94. Following the sale, the chief financial officer directly owned 133,303 shares in the company, valued at approximately $1,784,927.17. The trade was a 2.02% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 20.65% of the company's stock.

Institutional Investors Weigh In On Lifevantage

Several institutional investors and hedge funds have recently made changes to their positions in LFVN. Capital Management Corp VA lifted its holdings in Lifevantage by 77.0% in the 2nd quarter. Capital Management Corp VA now owns 1,266,110 shares of the company's stock valued at $16,561,000 after purchasing an additional 550,607 shares in the last quarter. Driehaus Capital Management LLC purchased a new position in Lifevantage in the 1st quarter valued at about $6,701,000. Wasatch Advisors LP lifted its holdings in Lifevantage by 6.6% in the 2nd quarter. Wasatch Advisors LP now owns 446,341 shares of the company's stock valued at $5,838,000 after purchasing an additional 27,765 shares in the last quarter. Acadian Asset Management LLC lifted its holdings in Lifevantage by 47.3% in the 1st quarter. Acadian Asset Management LLC now owns 291,700 shares of the company's stock valued at $4,248,000 after purchasing an additional 93,661 shares in the last quarter. Finally, Geode Capital Management LLC lifted its holdings in Lifevantage by 106.1% in the 2nd quarter. Geode Capital Management LLC now owns 245,332 shares of the company's stock valued at $3,210,000 after purchasing an additional 126,274 shares in the last quarter. 35.32% of the stock is currently owned by hedge funds and other institutional investors.

About Lifevantage

LifeVantage Corporation engages in the identification, research, development, formulation, and sale of advanced nutrigenomic activators, dietary supplements, nootropics, pre- and pro-biotics, weight management, skin and hair care, bath and body, and targeted relief products. It offers Protandim, a dietary supplement; LifeVantage Omega+, a dietary supplement that combines DHA and EPA Omega-3 fatty acids, Omega-7 fatty acids, and vitamin D3; LifeVantage ProBio, a dietary supplement to support gut health; PhysIQ, a weight management system; LifeVantage IC Bright, a supplement to support eye and brain health, reduce eye fatigue and strain, supports cognitive functions, and support normal sleep patterns; Petandim for Dogs, a supplement to combat oxidative stress in dogs; and Axio, a nootropic energy drink mix.